Skip to main content

The University of Pittsburgh Medical Center (UPMC) Children’s Hospital of Pittsburgh implanted their first patient with a reSept ASD Occluder. They are the second enrolling center in Pennsylvania participating in the ASCENT ASD study.

The patient had a congenital atrial septal defect (ASD), a hole between the upper chambers of the heart, that required closing. Bryan Goldstein, MD, Professor of Pediatrics and Director of Cardiac Catheterization and Intervention at UPMC Children’s successfully conducted the minimally invasive cardiac intervention with his team, implanting reSept as part of the trial.

“I see a future for a hybrid device for ASD closure that has less metal and a resorbable frame, potentially offering a long-term perspective to treatment, particularly to future transseptal interventions,” said Dr. Goldstein. “The 10-year efficacy data from previous studies on this device, recently presented, are a promising platform for further research. I am pleased to contribute to it in Pittsburgh, offering an investigational option to suitable patients.”

The ASCENT ASD Study

In addition to UPMC, the reSept ASD Occluder is being implanted in Pennsylvania at Children’s Hospital of Philadelphia, and in over 20 other centers in the USA, Canada, France and Switzerland, as part of the ASCENT ASD research study.

Atrial Septal Defects

An atrial septal defect is a hole in the wall called septum that separates the heart upper chambers called atria and that generally doesn’t close properly at birth. ASDs are among the most common congenital heart defects in children.

Most patients can be treated with an ASD occluder through a minimally invasive transcatheter procedure. Currently available occluders have a metal frame that stays in a patient’s heart for life. reSept is the first ASD occluder with a bioresorbable, metal-free frame currently in pivotal phase in the ASCENT ASD study

Please find further information on ASDs here.